1. Home
  2. MGX vs LPSN Comparison

MGX vs LPSN Comparison

Compare MGX & LPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGX
  • LPSN
  • Stock Information
  • Founded
  • MGX 2018
  • LPSN 1995
  • Country
  • MGX United States
  • LPSN United States
  • Employees
  • MGX N/A
  • LPSN N/A
  • Industry
  • MGX
  • LPSN EDP Services
  • Sector
  • MGX
  • LPSN Technology
  • Exchange
  • MGX NYSE
  • LPSN Nasdaq
  • Market Cap
  • MGX 65.0M
  • LPSN 71.2M
  • IPO Year
  • MGX 2024
  • LPSN 2000
  • Fundamental
  • Price
  • MGX $1.53
  • LPSN $0.85
  • Analyst Decision
  • MGX Strong Buy
  • LPSN Hold
  • Analyst Count
  • MGX 4
  • LPSN 4
  • Target Price
  • MGX $14.75
  • LPSN $0.97
  • AVG Volume (30 Days)
  • MGX 354.0K
  • LPSN 771.5K
  • Earning Date
  • MGX 05-16-2025
  • LPSN 05-07-2025
  • Dividend Yield
  • MGX N/A
  • LPSN N/A
  • EPS Growth
  • MGX N/A
  • LPSN N/A
  • EPS
  • MGX N/A
  • LPSN N/A
  • Revenue
  • MGX $52,295,000.00
  • LPSN $292,025,000.00
  • Revenue This Year
  • MGX N/A
  • LPSN N/A
  • Revenue Next Year
  • MGX $6.95
  • LPSN $2.35
  • P/E Ratio
  • MGX N/A
  • LPSN N/A
  • Revenue Growth
  • MGX 16.84
  • LPSN N/A
  • 52 Week Low
  • MGX $1.23
  • LPSN $0.52
  • 52 Week High
  • MGX $8.18
  • LPSN $2.08
  • Technical
  • Relative Strength Index (RSI)
  • MGX 49.74
  • LPSN 51.74
  • Support Level
  • MGX $1.40
  • LPSN $0.77
  • Resistance Level
  • MGX $1.64
  • LPSN $0.99
  • Average True Range (ATR)
  • MGX 0.14
  • LPSN 0.06
  • MACD
  • MGX 0.00
  • LPSN 0.01
  • Stochastic Oscillator
  • MGX 48.52
  • LPSN 50.04

About MGX METAGENOMI INC

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

About LPSN LivePerson Inc.

LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.

Share on Social Networks: